TRCT
TRDA icon

Tower Research Capital (TRC)’s Entrada Therapeutics TRDA Stock Holding History

Tower Research Capital (TRC)’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5K Buy
2,916
+1,246
+75% +$11.9K ﹤0.01% 3483
2026
Q1 		$21.1K Sell
1,670
-267
-14% -$3.06K ﹤0.01% 3448
2025
Q4 		$19.9K Sell
1,937
-5,421
-74% -$45.7K ﹤0.01% 3103
2025
Q3 		$42.7K Buy
7,358
+3,463
+89% +$20.3K ﹤0.01% 2655
2025
Q2 		$26.2K Buy
3,895
+2,703
+227% +$21.7K ﹤0.01% 3517
2025
Q1 		$10.8K Sell
1,192
-354
-23% -$4.41K ﹤0.01% 3608
2024
Q4 		$26.7K Sell
1,546
-4,818
-76% -$87.3K ﹤0.01% 2971
2024
Q3 		$102K Buy
6,364
+3,484
+121% +$54.9K ﹤0.01% 2224
2024
Q2 		$41K Buy
2,880
+2,445
+562% +$34.8K ﹤0.01% 3244
2024
Q1 		$6.16K Sell
435
-5,345
-92% -$75.6K ﹤0.01% 4421
2023
Q4 		$87.2K Buy
5,780
+4,777
+476% +$70.8K ﹤0.01% 2747
2023
Q3 		$15.8K Buy
1,003
+409
+69% +$6.44K ﹤0.01% 3590
2023
Q2 		$8.99K Sell
594
-698
-54% -$9.62K ﹤0.01% 4350
2023
Q1 		$19K Buy
1,292
+845
+189% +$11.3K ﹤0.01% 3514
2022
Q4 		$6K Sell
447
-2,061
-82% -$36.1K ﹤0.01% 4774
2022
Q3 		$40K Buy
+2,508
New +$31.8K ﹤0.01% 3360
2022
Q2 		– Sell
-2,485
Closed -$23K – 6523
2022
Q1 		$23K Buy
2,485
+7
+0.3% +$75 ﹤0.01% 3406
2021
Q4 		$42K Buy
+2,478
New +$60.1K ﹤0.01% 2909

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Tower Research Capital (TRC)'s TRDA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Entrada Therapeutics (TRDA) stake by 75% in Q2 2026, buying an estimated $11.9K and bringing the position to 2,916 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3483.

Tower Research Capital (TRC) first reported a position in TRDA in Q4 2021 and has held it in 18 quarters since. The position peaked at $102K in Q3 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Tower Research Capital (TRC) held 2,916 shares of Entrada Therapeutics worth $21.5K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,246 Entrada Therapeutics shares in Q2 2026, an estimated $11.9K.
  • Entrada Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3483 holding.
  • Tower Research Capital (TRC) first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Entrada Therapeutics position peaked at $102K in Q3 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.